These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35959737)

  • 1. Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale.
    Kouamou V; Machekano R; Mapangisana T; Maposhere C; Munyati S; Mutsvangwa J; Shamu T; McCarty K; Katzenstein D; Manasa J
    AIDS Res Hum Retroviruses; 2022 Oct; 38(10):774-778. PubMed ID: 35959737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia.
    Luwaya EL; Mwape L; Bwalya K; Siakabanze C; Hamooya BM; Masenga SK
    PLoS One; 2024; 19(9):e0308869. PubMed ID: 39241081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
    Eron J; Hung CC; Baril JG; Slim J; Falcó V; Bogner J; Maggiolo F; Mills A; Sievers J; Man CY; Urbaityte R; Underwood M; Tenorio AR; Pappa KA; Wynne B; Koteff J; Gartland M; Smith KY; Aboud M
    J Acquir Immune Defic Syndr; 2020 May; 84(1):60-65. PubMed ID: 31977595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinic-based SAMBA-II vs centralized laboratory viral load assays among HIV-1 infected children, adolescents and young adults in rural Zimbabwe: A randomized controlled trial.
    Kouamou V; Machekano R; Mapangisana T; Maposhere C; Mutetwa R; Manasa J; Shamu T; McCarty K; Munyati S; Mutsvangwa J; Bogoshi M; Israelski D; Katzenstein D
    PLoS One; 2023; 18(2):e0281279. PubMed ID: 36787296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
    Kouamou V; Manasa J; Katzenstein D; McGregor AM; Ndhlovu CE; Makadzange AT
    AIDS; 2019 Sep; 33(11):1729-1737. PubMed ID: 31361272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe.
    Kouamou V; Washaya T; Ndhlovu CE; Manasa J
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment.
    Steegen K; Levin L; Evans D; Technau KG; Hans L
    Pediatr Infect Dis J; 2022 Oct; 41(10):827-834. PubMed ID: 35895893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics.
    Fokam J; Nka AD; Mamgue Dzukam FY; Efakika Gabisa J; Bouba Y; Tommo Tchouaket MC; Ka'e AC; Ngoufack Jagni Semengue E; Takou D; Moudourou S; Fainguem N; Pabo W; Nayang Mundo RA; Kengni Ngueko AM; Ambe Chenwi C; Flore Yimga J; Nnomo Zam MK; Simo Kamgaing R; Tangimpundu C; Kamgaing N; Njom-Nlend AE; Ndombo Koki P; Kesseng D; Ndiang Tetang S; Kembou E; Ebiama Lifanda L; Pamen B; Ketchaji A; Saounde Temgoua E; Billong SC; Zoung-Kanyi Bissek AC; Hadja H; Halle EG; Colizzi V; Perno CF; Sosso SM; Ndjolo A
    Medicine (Baltimore); 2023 May; 102(20):e33737. PubMed ID: 37335723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Effectiveness of Dolutegravir Implementation in Uganda: A Prospective Observational Cohort Study (DISCO), 48-Week Results.
    McCluskey SM; Muyindike WR; Nanfuka V; Omoding D; Komukama N; Barigye IT; Kansiime L; Tumusiime J; Aung TN; Stuckwisch A; Hedt-Gauthier B; Marconi VC; Moosa MS; Pillay D; Giandhari J; Lessells R; Gupta RK; Siedner MJ
    J Infect Dis; 2024 Sep; 230(3):e622-e630. PubMed ID: 38748986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
    Paton NI; Musaazi J; Kityo C; Walimbwa S; Hoppe A; Balyegisawa A; Asienzo J; Kaimal A; Mirembe G; Lugemwa A; Ategeka G; Borok M; Mugerwa H; Siika A; Odongpiny ELA; Castelnuovo B; Kiragga A; Kambugu A;
    Lancet HIV; 2022 Jun; 9(6):e381-e393. PubMed ID: 35460601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
    Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
    Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Tolerability of Tenofovir/Lamivudine/Dolutegravir among Antiretroviral Therapy Naive Human Immunodeficiency Virus Infected Patients of a Tertiary Care Center in Eastern India.
    Sengupta D; Ghosh S; Pain S; Chatterjee N
    J Assoc Physicians India; 2023 Sep; 71(9):72-74. PubMed ID: 38700305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal viral load outcomes of adults with HIV after detectable viremia on tenofovir, lamivudine, and dolutegravir.
    Sodeke O; Milligan K; Ezeuko I; Oladipo A; Emeh A; Bashorun A; Orisawayi O; Danjuma S; Onotu D; Boyd AM; Abutu A; Chun H; Vallabhaneni S
    AIDS; 2024 Sep; 38(11):1714-1719. PubMed ID: 38870005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment.
    Kouamou V; Varyani B; Shamu T; Mapangisana T; Chimbetete C; Mudzviti T; Manasa J; Katzenstein D
    AIDS Res Hum Retroviruses; 2020 Jul; 36(7):566-573. PubMed ID: 32138527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection.
    Scott LJ
    Drugs; 2020 Jan; 80(1):61-72. PubMed ID: 31865558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
    Semengue ENJ; Fokam J; Etame NK; Molimbou E; Chenwi CA; Takou D; Mossiang L; Meledie AP; Yagai B; Nka AD; Dambaya B; Teto G; Ka'e AC; Beloumou GA; Djupsa Ndjeyep SC; Abba A; Kengni AMN; Tommo Tchouaket MC; Bouba NP; Billong SC; Sosso SM; Colizzi V; Perno CF; Kouanfack C; Zoung-Kanyi Bissek AC; Eben-Moussi E; Santoro MM; Ceccherini-Silberstein F; Ndjolo A
    Viruses; 2022 Dec; 15(1):. PubMed ID: 36680058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study.
    Hui X; Gan X; Li Q; Sun W
    Curr HIV Res; 2022; 20(3):222-227. PubMed ID: 35570525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.